Dr. Teitell received MD/PhD degrees from UCLA, followed by postdoctoral studies at Harvard and UCSF. He trained in anatomic pathology at Brigham and Women’s Hospital, in clinical pathology at UCSF, and performed a fellowship in pediatric pathology at Los Angeles Children’s Hospital. Dr. Teitell is the Latta Endowed Professor of Pathology and Laboratory Medicine and Chief of the Division of Pediatric and Neonatal Pathology at UCLA. He is Director of the UCLA Jonsson Comprehensive Cancer Center, President of the Jonsson Cancer Center Foundation and Director of the UCLA Tumor Immunology Training Program. He currently holds professorships in Pathology and Laboratory Medicine, Pediatrics and Bioengineering. He is the NCAA Faculty Athletics Representative for UCLA Intercollegiate Athletics.
Dr. Teitell’s interdisciplinary and interconnected research program focuses on basic and translational mechanisms in lymphoma, stem cell metabolism, mitochondrial biology, and biotechnology. His laboratory generated the first in vivo model of mature B lymphocyte malignancies, which are the most common hematologic tumors, and provided a new model of germinal center B cell transformation. With Carla Koehler, his team discovered a new pathway and mechanism for the shuttling of nucleus-encoded small RNAs into and out of mitochondria, to regulate mitochondrial metabolites, function and energy metabolism. His group also studies pluripotent stem cell metabolism and uncovered new mechanisms that integrate mitochondrial function with control of the epigenome for regulating stem cell self-renewal and differentiation. More recently, he co-invented a live cell interferometer, a type of quantitative phase microscope, to identify cancer cell responses and resistance to therapeutic agents. His team also co-invented photothermal nanoblade, BLAST, and MitoPunch devices to transfer large objects (mitochondria, intracellular pathogens and others) into mammalian cells (tumor lines, primary cells, stem cells and others) for mechanistic studies and applications in regenerative medicine. These enabling inventions resulted in his co-founding of two biotechnology companies, NanoCav, LLC, and MET Biotechnology, Inc. Dr. Teitell has authored more than 200 original scientific papers, reviews, and book chapters and is an inventor on 17 patents. He is Phi Beta Kappa, a Scholar and Stohlman Scholar of the Leukemia and Lymphoma Society, and a member of the Association of American Physicians and the American Society of Clinical Investigators.
In service to the community, Dr. Teitell recently began on the Scientific Advisory Committee of the V Foundation, is the incoming chair of the University of California Cancer Consortium, is an EAB member for the UC San Diego Cancer Therapeutics Training Program, is member of the ICRF International Scientific Council, and is an incoming member of the NCI Subcommittee-A for Cancer Centers. In athletics administration, Dr. Teitell is the former Chair of the Pac-12 Conference Legislative Committee, Diversity Leadership Committee, Woman of the Year Nominating Committee, and Student-Athlete Health and Wellbeing Committee, and former Chair of the Mountain Pacific Sports Federation Administrative Committee.